Origami Therapeutics CEO on harnessing autophagy to precisely target disease-causing proteins in the brain.
Aptly-named US biotech Origami Therapeutics is working to redefine how neurodegenerative diseases are treated, building on the biological insight that many disorders are driven by dysfunctional or “misfolded” proteins. By harnessing the body’s own natural protein disposal systems, the company aims to restore disease-causing proteins to their proper structure or eliminate them altogether.